Alteryx, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

  • Newegg Commerce, Inc. (NASDAQ:NEGG) shares climbed 8.7% to $1.12 in pre-market trading after falling 5% on Friday.
  • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares rose 7.2% to $5.65 in pre-market trading. Iovance Therapeutics shares jumped 13% on Friday after the company announced the FDA extended its BLA Priority Review for lifileucel amid resource constraints.
  • Bitfarms Ltd. (NASDAQ:BITF) shares gained 6% to $1.24 in pre-market trading.
  • Nikola Corporation (NASDAQ:NKLA) rose 5.9% to $1.26 in pre-market trading after gaining over 3% on Friday.
  • Alteryx, Inc. (NYSE:AYX) shares gained 5.2% to $36.67 in pre-market trading. Morgan Stanley upgraded Alteryx from Equal-Weight to Overweight and announced a $54 price target.
  • TeraWulf Inc. (NASDAQ:WULF) shares rose 4.7% to $1.76 in pre-market trading. TeraWulf recently announced Aug. 2023 production and operations updates.
  • Hyatt Hotels Corporation (NYSE:H) shares climbed 4.7% to $112.54 in pre-market trading.
  • Kimbell Royalty Partners, LP (NYSE:KRP) shares gained 4.6% to $16.25 in pre-market trading. Kimbell Royalty Partners recently closed $455 million acquisition of Permian and Mid-Con mineral and royalty interests in cash transaction.
  • Calliditas Therapeutics AB (NASDAQ:CALT) shares gained 4.5% to $16.76 in pre-market trading. Calliditas Therapeutics is making significant strides in addressing rare kidney diseases. In a recent interview with Benzinga, the company’s CEO, Renee Aguiar-Lucander, provided valuable insights on various aspects of its work.

Now Read This: Investor Sentiment Declines After S&P 500 Falls For Second Straight Week

Don’t forget to check out our premarket coverage here

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs

Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...